Side effects of radiographic contrast media: Pathogenesis, risk factors, and prevention

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Andreucci, Michele ^a   Solomon, Richard ^b   Tasanarong, Adis ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c THAMMASAT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BUTYRIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANNITOL; NEBIVOLOL; PROSTAGLANDIN E1; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; STEROID; THIOREDOXIN;

ACUTE KIDNEY FAILURE; CONTRAST INDUCED NEPHROPATHY; CONTRAST INDUCED THYROID DYSFUNCTION; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMERGENCY MEDICINE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; HYPOTENSION; IMAGE ANALYSIS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY TUBULE DISORDER; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; THYROID DISEASE; X RAY; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; KIDNEY DISEASES; PATHOPHYSIOLOGY; RADIOGRAPHY; THYROID GLAND;

ANIMALS; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; RADIOGRAPHY; RISK FACTORS; THYROID GLAND;

EID: 84901801366     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/741018     Document Type: Review

References (235)

1. Lightfoot C. B., Abraham R. J., Mammen T., Abdolell M., Kapur S., Abraham R. J., Survey of radiologists' knowledge regarding the management of severe contrast material-induced allergic reactions. Radiology 2009 251 3 691 696 2-s2.0-67049086436 10.1148/radiol.2513081651
2. Singh J., Daftary A., Iodinated contrast media and their adverse reactions. Journal of Nuclear Medicine Technology 2008 36 2 69 76 2-s2.0-45849151283 10.2967/jnmt.107.047621 (Pubitemid 351879833)
3. Thomson K. R., Varma D. K., Safe use of radiographic contrast media. Australian Prescriber 2010 33 1 19 22 2-s2.0-76149130074
4. Loh S., Bagheri S., Katzberg R. W., Fung M. A., Li C., Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement. Radiology 2010 255 3 764 771 2-s2.0-77952716347 10.1148/radiol.10091848
5. Schild H. H., Kuhl C. K., Hübner-Steiner U., Böhm I., Speck U., Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology 2006 240 1 56 64 2-s2.0-33745133009 10.1148/radiol.2393050560 (Pubitemid 43902594)
6. Sutton A. G. C., Finn P., Grech E. D., Hall J. A., Stewart M. J., Davies A., de Belder M. A., Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. American Heart Journal 2001 141 4 677 683 2-s2.0-0035089178 10.1067/mhj.2001.113570 (Pubitemid 32260738)
7. Sutton A. G. C., Finn P., Campbell P. G., Price D. J. A., Hall J. A., Stewart M. J., Davies A., Linker N. J., Harcombe A. A., de Belder M. A., Early and late reactions following the use of iopamidol 340, iomeprol 350 and iodixanol 320 in cardiac catheterization. Journal of Invasive Cardiology 2003 15 3 133 138 2-s2.0-0037342989 (Pubitemid 36330935)
8. Sendeski M. M., Pathophysiology of renal tissue damage by iodinated contrast media. Clinical and Experimental Pharmacology and Physiology 2011 38 5 292 299 2-s2.0-79955390319 10.1111/j.1440-1681.2011.05503.x
9. van der Molen A. J., Thomsen H. S., Morcos S. K., Almén T., Aspelin P., Bellin M. F., Flaten H., Jakobsen J. Å., Krestin G. P., Löwe A., Oyen R., Stacul F., Webb J. A. W., Effect of iodinated contrast media on thyroid function in adults. European Radiology 2004 14 5 902 907 2-s2.0-2542496944 10.1007/s00330-004-2238-z (Pubitemid 38678914)
10. Katzberg R. W., Haller C., Contrast-induced nephrotoxicity: clinical landscape. Kidney International. Supplement 2006 69 S3 S7 2-s2.0-33746919048 10.1038/sj.ki.5000366
11. Moisey R. S., McPherson S., Wright M., Orme S. M., Thyroiditis and iodide mumps following an angioplasty. Nephrology Dialysis Transplantation 2007 22 4 1250 1252 2-s2.0-34047186379 10.1093/ndt/gfl777 (Pubitemid 46523448)
12. Trumbo P., Yates A. A., Schlicker S., Poos M., Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Journal of the American Dietetic Association 2001 101 3 294 301 2-s2.0-0035289903
13. Leung A. M., Braverman L. E., Iodine-induced thyroid dysfunction. Current Opinion in Endocrinology, Diabetes, and Obesity 2012 19 414 419
14. Eng P. H. K., Cardona G. R., Fang S., Previti M., Alex S., Carrasco N., Chin W. W., Braverman L. E., Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999 140 8 3404 3410 2-s2.0-0033305353 (Pubitemid 30645394)
15. Martins M. C., Lima N., Knobel M., Medeiros-Neto G., Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up. Journal of Endocrinological Investigation 1989 12 4 239 244 2-s2.0-0024378252 (Pubitemid 19144176)
16. Bürgi H., Iodine excess. Best Practice and Research: Clinical Endocrinology and Metabolism 2010 24 1 107 115 2-s2.0-76749114458 10.1016/j.beem.2009.08.010
17. Rhee C. M., Bhan I., Alexander E. K., Brunelli S. M., Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Archives of Internal Medicine 2012 172 2 153 159 2-s2.0-84856190005 10.1001/archinternmed.2011.677
18. Martin F. I. R., Tress B. W., Colman P. G., Deam D. R., Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. American Journal of Medicine 1993 95 1 78 82 2-s2.0-0027303055 10.1016/0002-9343(93) 90235-H (Pubitemid 23205930)
19. Conn J. J., Sebastian M. J., Deam D., Tam M., Martin F. I. R., A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 1996 6 2 107 110 2-s2.0-0029930312 (Pubitemid 26153007)
20. Hintze G., Blombach O., Fink H., Burkhardt U., Köbberling J., Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. European Journal of Endocrinology 1999 140 3 264 267 2-s2.0-0032942726 (Pubitemid 29155586)
21. Gartner W., Weissel M., Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week? Thyroid 2004 14 7 521 524 2-s2.0-3543039413 10.1089/1050725041517075 (Pubitemid 39014590)
22. Panzer C., Beazley R., Braverman L., Rapid preoperative preparation for severe hyperthyroid Graves' disease. Journal of Clinical Endocrinology and Metabolism 2004 89 5 2142 2144 2-s2.0-2442568586 10.1210/jc.2003-031981 (Pubitemid 38619843)
23. Gleeson T. G., Bulugahapitiya S., Contrast-induced nephropathy. American Journal of Roentgenology 2004 183 6 1673 1689 2-s2.0-16644390328 (Pubitemid 44210538)
24. Curtis L. M., Agarwal A., HOpe for contrast-induced acute kidney injury. Kidney International 2007 72 8 907 909 2-s2.0-34948907908 10.1038/sj.ki.5002530 (Pubitemid 47530580)
25. Solomon R., Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clinical Journal of the American Society of Nephrology 2008 3 5 1242 1243 2-s2.0-53749093136 10.2215/CJN.03470708
26. Katzberg R. W., Newhouse J. H., Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010 256 1 21 28 2-s2.0-77953938050 10.1148/radiol.10092000
27. Thomsen H. S., Morcos S. K., Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. British Journal of Radiology 2003 76 908 513 518 2-s2.0-0041932452 10.1259/bjr/26964464 (Pubitemid 37028403)
28. Mehran R., Nikolsky E., Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney International. Supplement 2006 100 S11 S15 2-s2.0-33746926391
29. Newhouse J. H., Kho D., Rao Q. A., Starren J., Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. American Journal of Roentgenology 2008 191 2 376 382 2-s2.0-49149099592 10.2214/AJR.07.3280
30. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 1999 130 6 461 470 2-s2.0-0033574249 (Pubitemid 29135798)
31. Cockcroft D. W., Gault M. H., Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 1 31 41 2-s2.0-0016916438
32. Scanlon P. J., Faxon D. P., Audet A. M., Carabello B., Dehmer G. J., Eagle K. A., Legako R. D., Leon D. F., Murray J. A., Nissen S. E., Pepine C. J., Watson R. M., Ritchie J. L., Gibbons R. J., Cheitlin M. D., Gardner T. J., Garson A. Jr., Russell R. O. Jr., Ryan T. J., Smith S. C. Jr., ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. Journal of the American College of Cardiology 1999 33 1756 1824
33. McCullough P. A., Wolyn R., Rocher L. L., Levin R. N., O'Neill W. W., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. American Journal of Medicine 1997 103 5 368 375 2-s2.0-0030661687 10.1016/S0002-9343(97)00150-2 (Pubitemid 27506242)
34. Mitchell A. M., Jones A. E., Tumlin J. A., Kline: J. A., Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clinical Journal of the American Society of Nephrology 2010 5 4 9
35. Weisbord S. D., Mor M. K., Resnick A. L., Hartwig K. C., Palevsky P. M., Fine M. J., Incidence and outcomes of contrast-induced AKI following computed tomography. Clinical Journal of the American Society of Nephrology 2008 3 5 1274 1281 2-s2.0-53749085373 10.2215/CJN.01260308
36. Bruce R. J., Djamali A., Shinki K., Michel S. J., Fine J. P., Pozniak M. A., Background fluctuation of kidney function versus contrast-induced nephrotoxicity. American Journal of Roentgenology 2009 192 3 711 718 2-s2.0-63049086302 10.2214/AJR.08.1413
37. Davenport M. S., Khalatbari S., Cohan R. H., Dillman J. R., Myles J. D., Ellis J. H., Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013 268 719 728
38. Davenport M. S., Khalatbari S., Dillman J. R., Cohan R. H., Caoili E. M., Ellis J. H., Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 2013 267 94 105
39. McDonald R. J., McDonald J. S., Bida J. P., Carter R. E., Fleming C. J., Misra S., Williamson E. E., Kallmes D. F., Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 2013 267 106 118
40. McDonald J. S., McDonald R. J., Comin J., Williamson E. E., Katzberg R. W., Murad M. H., Kallmes D. F., Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 2013 267 119 128
41. Rudnick M., Feldman H., Contrast-induced nephropathy: what are the true clinical consequences? Clinical Journal of the American Society of Nephrology 2008 3 1 263 272 2-s2.0-38749119810 10.2215/CJN.03690907
42. Lakhal K., Ehrmann S., Chaari A., Laissy J., Régnier B., Wolff M., Pajot O., Acute Kidney Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and outcome. Journal of Critical Care 2011 26 6 593 599 2-s2.0-81955168062 10.1016/j.jcrc.2011.05.010
43. Solomon R. J., Mehran R., Natarajan M. K., Doucet S., Katholi R. E., Staniloae C. S., Sharma S. K., Labinaz M., Gelormini J. L., Barrett B. J., Contrast-induced nephropathy and long-term adverse events: cause and effect? Clinical Journal of the American Society of Nephrology 2009 4 7 1162 1169 2-s2.0-66149188637 10.2215/CJN.00550109
44. Giaccia A. J., Simon M. C., Johnson R., The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes and Development 2004 18 18 2183 2194 2-s2.0-4444257379 10.1101/gad.1243304 (Pubitemid 39209567)
45. Heyman S. N., Rosen S., Khamaisi M., Idée J., Rosenberger C., Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Investigative Radiology 2010 45 4 188 195 2-s2.0-77949867992 10.1097/RLI.0b013e3181d2eed8
46. Dawson P., Harrison M. J. G., Weisblatt E., Effect of contrast media on red cell filtrability and morphology. British Journal of Radiology 1983 56 670 707 710 2-s2.0-0020557795 (Pubitemid 13007399)
47. Murphy S. W., Barrett B. J., Parfrey P. S., Contrast nephropathy. Journal of the American Society of Nephrology 2000 11 1 177 182 2-s2.0-0033982499 (Pubitemid 30020439)
48. Detrenis S., Meschi M., Musini S., Savazzi G., Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrology Dialysis Transplantation 2005 20 8 1542 1550 2-s2.0-26444608615 10.1093/ndt/gfh868 (Pubitemid 41418575)
49. Fishbane S., N-acetylcysteine in the prevention of contrast-induced nephropathy. Clinical Journal of the American Society of Nephrology 2008 3 1 281 287 2-s2.0-38749139299 10.2215/CJN.02590607
50. Sendeski M., Patzak A., Pallone T. L., Cao C., Persson A. E., Persson P. B., Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009 251 3 697 704 2-s2.0-67049171046 10.1148/radiol.2513081732
51. Pacher P., Beckman J. S., Liaudet L., Nitric oxide and peroxynitrite in health and disease. Physiological Reviews 2007 87 1 315 424 2-s2.0-33846863589 10.1152/physrev.00029.2006 (Pubitemid 46217686)
52. Myers S. I., Wang L., Liu F., Bartula L. L., Iodinated contrast induced renal vasoconstriction is due in part to the downregulation of renal cortical and medullary nitric oxide synthesis. Journal of Vascular Surgery 2006 44 2 383 391 2-s2.0-33746557515 10.1016/j.jvs.2006.04.036 (Pubitemid 44142933)
53. Pisani A., Sabbatini M., Riccio E., Rossano R., Andreucci M., Capasso C., de Luca V., Carginale V., Bizzarri M., Borrelli A., Schiattarella A., Santangelo M., Mancini A., Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clinical and Experimental Nephrology 2013 10.1007/s10157-013-0828-2
54. Heyman S. N., Rosen S., Rosenberger C., Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clinical Journal of the American Society of Nephrology 2008 3 1 288 296 2-s2.0-38749112993 10.2215/CJN.02600607
55. Hardiek K., Katholi R. E., Ramkumar V., Deitrick C., Proximal tubule cell response to radiographic contrast media. The American Journal of Physiology-Renal Physiology 2001 280 1 F61 F70 2-s2.0-0034997953
56. Heinrich M. C., Kuhlmann M. K., Grgic A., Heckmann M., Kramann B., Uder M., Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005 235 3 843 849 2-s2.0-18844397603 10.1148/radiol.2353040726 (Pubitemid 40695879)
57. Andreucci M., Lucisano G., Faga T., Bertucci B., Tamburrini O., Pisani A., Sabbatini M., Salzano S., Vitale M., Fuiano G., Michael A., Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. Toxicological Sciences 2011 119 2 408 416 2-s2.0-78751688950 10.1093/toxsci/kfq332
58. Andreucci M., Fuiano G., Presta P., Esposito P., Faga T., Bisesti V., Procino A., Altieri V., Tozzo C., Memoli B., Michael A., Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochemical Pharmacology 2006 72 10 1334 1342 2-s2.0-33750201137 10.1016/j.bcp.2006.08.008 (Pubitemid 44604287)
59. Andreucci M., Faga T., Russo D., Bertucci B., Tamburrini O., Pisani A., Sabbatini M., Fuiano G., Michael A., Differential activation of signaling pathways by low-osmolar and iso-osmolar radiocontrast agents in human renal tubular cells. Journal of Cellular Biochemistry 2014 115 281 289
60. Michael, A., Faga, T., Pisani, A., Riccio, E., Bramanti, P., Sabbatini, M., Navarra, M., Andreucci, M., Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Side Effects of Radiographic Contrast, Media 2014 BioMed Research International Special Issue
61. 2-treated human renal proximal tubular cells. Chemico-Biological Interactions 2010 185 3 253 262 2-s2.0-77952294468 10.1016/j.cbi.2010.03.019
62. Persson P. B., Hansell P., Liss P., Pathophysiology of contrast medium-induced nephropathy. Kidney International 2005 68 1 14 22 2-s2.0-24944514021 10.1111/j.1523-1755.2005.00377.x (Pubitemid 43181360)
63. Cunha M. A., Schor N., Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells. Renal Failure 2002 24 5 655 658 2-s2.0-0036385763 10.1081/JDI-120013970
64. Peer A., Averbukh Z., Berman S., Modai D., Averbukh M., Weissgarten J., Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Investigative Radiology 2003 38 3 177 182 2-s2.0-0346666971 10.1097/00004424-200303000-00007 (Pubitemid 36255290)
65. Haller C., Hizoh I., The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Investigative Radiology 2004 39 3 149 154 2-s2.0-1342281090 10.1097/01.rli.0000113776.87762.49 (Pubitemid 38263921)
66. McCullough P. A., Acute kidney injury with iodinated contrast. Critical Care Medicine 2008 36 S204 S211 2-s2.0-41649088873 10.1097/CCM.0b013e318168cdc3 (Pubitemid 351483053)
67. Weisbord S. D., Iodinated contrast media and the kidney. Reviews in Cardiovascular Medicine 2008 9 supplement 1 S14 S23 2-s2.0-42249092315 (Pubitemid 351550377)
68. Osthoff M., Piezzi V., Klima T., Christ A., Marana I., Hartwiger S., Breidthardt T., Marenzi G., Trendelenburg M., Mueller C., Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrology 2012 13, article 99
69. Dharnidharka V. R., Kwon C., Stevens G., Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. American Journal of Kidney Diseases 2002 40 2 221 226 2-s2.0-0036329067 10.1053/ajkd.2002.34487 (Pubitemid 34827638)
70. Herget-Rosenthal S., Marggraf G., Hüsing J., Göring F., Pietruck F., Janssen O., Philipp T., Kribben A., Early detection of acute renal failure by serum cystatin C. Kidney International 2004 66 3 1115 1122 2-s2.0-4344672550 10.1111/j.1523-1755.2004.00861.x (Pubitemid 39121017)
71. Rickli H., Benou K., Ammann P., Fehr T., Brunner-La Rocca H. P., Petridis H., Riesen W., Wüthrich R. P., Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clinical Nephrology 2004 61 2 98 102 2-s2.0-1242273872 (Pubitemid 38219904)
72. Kimmel M., Butscheid M., Brenner S., Kuhlmann U., Klotz U., Alscher D. M., Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc-preliminary results. Nephrology Dialysis Transplantation 2008 23 4 1241 1245 2-s2.0-42949106192 10.1093/ndt/gfm785 (Pubitemid 351767504)
73. Morcos S. K., Thomsen H. S., Webb J. A. W., Contrast-media-induced nephrotoxicity: a consensus report. European Radiology 1999 9 8 1602 1613 2-s2.0-0032606029 10.1007/s003300050894
74. Neyra J. A., Shah S., Mooney R., Jacobsen G., Yee J., Novak J. E., Contrast-induced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease. Nephrology Dialysis Transplantation 2013 28 1463 1471
75. Hardiek K. J., Katholi R. E., Robbs R. S., Katholi C. E., Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. Journal of Diabetes and its Complications 2008 22 3 171 177 2-s2.0-42349099179 10.1016/j.jdiacomp.2006.11.002 (Pubitemid 351552047)
76. Khamaisi M., Raz I., Shilo V., Shina A., Rosenberger C., Dahan R., Abassi Z., Meidan R., Lecht S., Heyman S. N., Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney International 2008 74 1 91 100 2-s2.0-45249109079 10.1038/ki.2008.112 (Pubitemid 351841889)
77. Pflueger A., Larson T. S., Nath K. A., King B. F., Gross J. M., Knox F. G., Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clinic Proceedings 2000 75 12 1275 1283 2-s2.0-0033673343
78. Pakfetrat M., Nikoo M. H., Malekmakan L., Tabande M., Roozbeh J., Ganbar Ali R. J., Khajehdehi P., Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes. Hemodialysis International 2010 14 4 387 392 2-s2.0-77958525985 10.1111/j.1542-4758.2010. 00469.x
79. Morabito S., Pistolesi V., Benedetti G., di Roma A., Colantonio R., Mancone M., Sardella G., Cibelli L., Ambrosino M., Polistena F., Pierucci A., Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. Journal of Nephrology 2012 25 1098 1107
80. Rudnick M. R., Goldfarb S., Tumlin J., Contrast-induced nephropathy: is the picture any clearer? Clinical Journal of the American Society of Nephrology 2008 3 1 261 262 2-s2.0-38749125921 10.2215/CJN.04951107
81. Manske C. L., Sprafka J. M., Strony J. T., Wang Y., Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. American Journal of Medicine 1990 89 5 615 620 2-s2.0-0024990320 10.1016/0002-9343(90)90180-L (Pubitemid 20384319)
82. Morcos S. K., Contrast media-induced nephrotoxicity-questions and answers. British Journal of Radiology 1998 71 357 365 2-s2.0-0031966685 (Pubitemid 28176795)
83. Kolonko A., Kokot F., Wicek A., Contrast-associated nephropathy-old clinical problem and new therapeutic perspectives. Nephrology Dialysis Transplantation 1998 13 3 803 806 2-s2.0-0031885722 10.1093/ndt/13.3.803 (Pubitemid 28119084)
84. Toprak O., Conflicting and new risk factors for contrast induced nephropathy. The Journal of Urology 2007 178 6 2277 2283 2-s2.0-35748940592 10.1016/j.juro.2007.08.054 (Pubitemid 350052198)
85. Schoolwerth A. C., Sica D. A., Ballermann B. J., Wilcox C. S., Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the american heart association. Circulation 2001 104 16 1985 1991 2-s2.0-0035899896 (Pubitemid 32983246)
86. Cirit M., Toprak O., Yesil M., Bayata S., Postaci N., Pupim L., Esi E., Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron-Clinical Practice 2006 104 1 c20 c27 2-s2.0-33747075921 10.1159/000093255
87. Kiski D., Stepper W., Brand E., Breithardt G., Reinecke H., Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrology Dialysis Transplantation 2010 25 3 759 764 2-s2.0-77649200557 10.1093/ndt/gfp582
88. Rim M. Y., Ro H., Kang W. C., Kim A. J., Park H., Chang J. H., Lee H. H., Chung W., Jung J. Y., The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. American Journal of Kidney Diseases 2012 60 576 582
89. Umruddin Z., Moe K., Superdock K., ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. Journal of Nephrology 2012 25 776 781
90. Onuigbo M. A. C., Onuigbo N. T. C., Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month mayo clinic study. Renal Failure 2008 30 1 67 72 2-s2.0-38149056577 10.1080/08860220701742153
91. Gupta R. K., Kapoor A., Tewari S., Sinha N., Sharma R. K., Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart Journal 1999 51 5 521 526 2-s2.0-0033509991 (Pubitemid 30139601)
92. Duan S. B., Wang Y. H., Liu F. Y., Xu X. Q., Wang P., Zou Q., Peng Y. M., The protective role of telmisartan against nephrotoxicity induced by x-ray contrast media in rat model. Acta Radiologica 2009 50 7 754 759 2-s2.0-69949124716 10.1080/02841850902995544
93. Rosenstock J. L., Bruno R., Kim J. K., Lubarsky L., Schaller R., Panagopoulos G., DeVita M. V., Michelis M. F., The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. International Urology and Nephrology 2008 40 3 749 755 2-s2.0-48549097956 10.1007/s11255-008-9368-1
94. Group K. D. I. G.O.K.A.K.I.W., KDIGO clinical practice guideline for acute kidney injury. Kidney Interantional 2012 2 1 138
95. Barrett B. J., Parfrey P. S., Prevention of nephrotoxicity induced by radiocontrast agents. The New England Journal of Medicine 1994 331 21 1449 1450 2-s2.0-0028000001 10.1056/NEJM199411243312111 (Pubitemid 24348362)
96. Bartels E. D., Brun G. C., Gammeltoft A., Gjorup P. A., Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Medica Scandinavica 1954 150 297 302
97. Perillie P. E., Conn H. O., Acute renal failure after intravenous pyelography in plasma cell myeloma. Journal of the American Medical Association 1958 167 2186 2189
98. Scheitlin W., Martz G., Brunner U., Acute renal failure following intravenous pyelography in multiple myeloma. Schweizerische Medizinische Wochenschrift 1960 90 84 87 2-s2.0-33646162588
99. Myers G. H. Jr., Witten D. M., Acute renal failure after excretory urography in multiple myeloma. The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1971 113 3 583 588 2-s2.0-0015156632
100. Cohen D. J., Sherman W. H., Osserman E. F., Appel G. B., Acute renal failure in patients with multiple myeloma. American Journal of Medicine 1984 76 2 247 256 2-s2.0-0021361068 (Pubitemid 14157839)
101. McCarthy C. S., Becker J. A., Multiple myeloma and contrast media. Radiology 1992 183 2 519 521 2-s2.0-0026631029
102. Pahade J. K., LeBedis C. A., Raptopoulos V. D., Avigan D. E., Yam C. S., Kruskal J. B., Pedrosa I., Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. American Journal of Roentgenology 2011 196 5 1094 1101 2-s2.0-79959602173 10.2214/AJR.10.5152
103. Dawnay A. B., Thornley C., Nockler I., Webb J. A., Cattel W. R., Tamm-Horsfall glycoprotein excretion and aggregation during intravenous urography: relevance to acute renal failure. Investigative Radiology 1985 20 1 53 57 2-s2.0-0021987772 (Pubitemid 15162084)
104. Cochran S. T., Wong W. S., Roe D. J., Predicting angiography-induced acute renal function impairment: clinical risk model. American Journal of Roentgenology 1983 141 5 1027 1033 2-s2.0-0020514734 (Pubitemid 13021405)
105. Oliveira D. B. G., Prophylaxis against contrast-induced nephropathy. The Lancet 1999 353 9165 1638 1639 2-s2.0-0033562644 10.1016/S0140-6736(98)90076-9 (Pubitemid 29224517)
106. Taliercio C. P., Vlietstra R. E., Fisher L. D., Burnett J. C., Risks for renal dysfunction with cardiac angiography. Annals of Internal Medicine 1986 104 4 501 504 2-s2.0-0022621983 (Pubitemid 16137810)
107. McCullough P., Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheterization and Cardiovascular Interventions 2006 67 3 335 343 2-s2.0-33644765768 10.1002/ccd.20658 (Pubitemid 43346729)
108. Kato K., Sato N., Yamamoto T., Iwasaki Y., Tanaka K., Mizuno K., Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circulation Journal 2008 72 9 1499 1505 2-s2.0-50449090439 10.1253/circj.CJ-07-1006
109. Nunag M., Brogan M., Garrick R., Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. Cardiology in Review 2009 17 6 263 269 2-s2.0-73949122307 10.1097/CRD.0b013e3181bc359d
110. Byrd L., Sherman R. L., Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine 1979 58 3 270 279 2-s2.0-0018391207 (Pubitemid 9185650)
111. Harkonen S., Kjellstrand C., Contrast nephropathy. American Journal of Nephrology 1981 1 2 69 77 2-s2.0-0019827735 (Pubitemid 11023075)
112. Khoury G. A., Hopper J. C., Varghese Z., Farrington K., Dick R., Irving J. D., Sweny P., Fernando O. N., Moorhead J. F., Nephrotoxicity of ionic and non-ionic contrast material in digital vascular imaging and selective renal arteriography. British Journal of Radiology 1983 56 669 631 635 2-s2.0-0020595121 (Pubitemid 13045446)
113. Moore R. D., Steinberg E. P., Powe N. R., Brinker J. A., Fishman E. K., Graziano S., Gopalan R., Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992 182 3 649 655 2-s2.0-0026599467
114. Katzberg R. W., Barrett B. J., Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology 2007 243 3 622 628 2-s2.0-34249096874 10.1148/radiol.2433061411 (Pubitemid 46799414)
115. Dong M., Jiao Z., Liu T., Guo F., Li G., Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. Journal of Nephrology 2012 25 290 301
116. Campbell D. R., Flemming B. K., Mason W. F., Jackson S. A., Hirsch D. J., MacDonald K. J., A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Canadian Association of Radiologists Journal 1990 41 3 133 137 2-s2.0-0025317014 (Pubitemid 20202597)
117. Gomes A. S., Baker J. D., Martin-Paredero V., Dixon S. M., Takiff H., Machleder H. I., Moore W. S., Acute renal dysfunction after major arteriography. American Journal of Roentgenology 1985 145 6 1249 1253 2-s2.0-0022340956 (Pubitemid 16202634)
118. Aspelin P., Aubry P., Fransson S., Strasser R., Willenbrock R., Berg K. J., Nephrotoxic effects in high-risk patients undergoing angiography. The New England Journal of Medicine 2003 348 6 491 499 2-s2.0-0037421597 10.1056/NEJMoa021833 (Pubitemid 36159884)
119. Katzberg R. W., Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997 204 2 297 312 2-s2.0-0030742750 (Pubitemid 27337471)
120. Taliercio C. P., Vlietstra R. E., Ilstrup D. M., Burnett J. C., Menke K. K., Stensrud S. L., Holmes D. R. Jr., A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. Journal of the American College of Cardiology 1991 17 2 384 390 2-s2.0-0025884525
121. Barrett B. J., Carlisle E. J., Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993 188 1 171 178 2-s2.0-0027301087 (Pubitemid 23183119)
122. Barrett B. J., Contrast nephrotoxicity. Journal of the American Society of Nephrology 1994 5 2 125 137 2-s2.0-0028490756 (Pubitemid 24977068)
123. Chalmers N., Jackson R. W., Comparison of iodixanol and iohexol in renal impairment. British Journal of Radiology 1999 72 701 703 2-s2.0-0032799505 (Pubitemid 29355616)
124. Heinrich M. C., Häberle L., Müller V., Bautz W., Uder M., Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009 250 1 68 86 2-s2.0-58149331038 10.1148/radiol.2501080833
125. Solomon R. J., Natarajan M. K., Doucet S., Sharma S. K., Staniloae C. S., Katholi R. E., Gelormini J. L., Labinaz M., Moreyra A. E., Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007 115 25 3189 3196 2-s2.0-34347345064 10.1161/CIRCULATIONAHA.106. 671644 (Pubitemid 47012233)
126. Reed M., Meier P., Tamhane U. U., Welch K. B., Moscucci M., Gurm H. S., The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC: Cardiovascular Interventions 2009 2 7 645 654 2-s2.0-67650709416 10.1016/j.jcin.2009.05.002
127. Bolognese L., Falsini G., Schwenke C., Grotti S., Limbruno U., Liistro F., Carrera A., Angioli P., Picchi A., Ducci K., Pierli C., Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] trial). The American Journal of Cardiology 2012 109 1 67 74 2-s2.0-83555176062 10.1016/j.amjcard.2011.08.006
128. Nikolsky E., Mehran R., Lasic Z., Mintz G. S., Lansky A. J., Na Y., Pocock S., Negoita M., Moussa I., Stone G. W., Moses J. W., Leon M. B., Dangas G., Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney International 2005 67 2 706 713 2-s2.0-19944432027 10.1111/j.1523-1755.2005.67131.x (Pubitemid 40139864)
129. Ahuja T. S., Niaz N., Agraharkar M., Contrast-induced nephrotoxicity in renal allograft recipients. Clinical Nephrology 2000 54 1 11 14 2-s2.0-0033921696 (Pubitemid 30456799)
130. Mueller C., Prevention of contrast-induced nephropathy with volume supplementation. Kidney International. Supplement 2006 100 S16 S19 2-s2.0-33746864932
131. Ellis J. H., Cohan R. H., Prevention of contrast-induced nephropathy: an overview. Radiologic Clinics of North America 2009 47 5 801 811 2-s2.0-69649092592 10.1016/j.rcl.2009.06.003
132. Solomon R., Dauerman H. L., Contrast-induced acute kidney injury. Circulation 2010 122 23 2451 2455 2-s2.0-78650703473 10.1161/CIRCULATIONAHA.110. 953851
133. Balemans C. E., Reichert L. J., van Schelven B. I., van den Brand J. A., Wetzels J. F., Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology 2012 263 706 713
134. Thomsen H. S., Guidelines for contrast media from the European Society of Urogenital Radiology. American Journal of Roentgenology 2003 181 6 1463 1471 2-s2.0-0345275907 (Pubitemid 37466517)
135. Solomon R., Werner C., Mann D., D'Elia J., Silva P., Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. The New England Journal of Medicine 1994 331 21 1416 1420 2-s2.0-0028033015 10.1056/NEJM199411243312104 (Pubitemid 24348355)
136. Merten G. J., Burgess W. P., Gray L. V., Holleman J. H., Roush T. S., Kowalchuk G. J., Bersin R. M., Van Moore A., Simonton C. A. III, Rittase R. A., Norton H. J., Kennedy T. P., Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. Journal of the American Medical Association 2004 291 19 2328 2334 2-s2.0-2442590642 10.1001/jama.291.19. 2328 (Pubitemid 38656299)
137. Masuda M., Yamada T., Mine T., Morita T., Tamaki S., Tsukamoto Y., Okuda K., Iwasaki Y., Hori M., Fukunami M., Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. The American Journal of Cardiology 2007 100 5 781 786 2-s2.0-34547947413 10.1016/j.amjcard.2007.03.098 (Pubitemid 47268267)
138. Ozcan E. E., Guneri S., Akdeniz B., Akyildiz I. Z., Senaslan O., Baris N., Aslan O., Badak O., Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. American Heart Journal 2007 154 3 539 544 2-s2.0-34547944556 10.1016/j.ahj.2007.05.012 (Pubitemid 47268251)
139. Tamura A., Goto Y., Miyamoto K., Naono S., Kawano Y., Kotoku M., Watanabe T., Kadota J., Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. The American Journal of Cardiology 2009 104 7 921 925 2-s2.0-70249117867 10.1016/j.amjcard.2009.05.034
140. Navaneethan S. D., Singh S., Appasamy S., Wing R. E., Sehgal A. R., Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. American Journal of Kidney Diseases 2009 53 4 617 627 2-s2.0-62749137422 10.1053/j.ajkd.2008.08.033
141. Hoste E. A. J., de Waele J. J., Gevaert S. A., Uchino S., Kellum J. A., Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrology Dialysis Transplantation 2010 25 3 747 758 2-s2.0-77649204848 10.1093/ndt/gfp389
142. Joannidis M., Schmid M., Wiedermann C. J., Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wiener Klinische Wochenschrift 2008 120 23-24 742 748 2-s2.0-58149303226 10.1007/s00508-008-1117-z
143. Jang J. S., Jin H. Y., Seo J. S., Yang T. H., Kim D. K., Kim T. H., Urm S. H., Kim D. S., Kim D. K., Seol S. H., Kim D. I., Cho K. I., Kim B. H., Park Y. H., Je H. G., Ahn J. M., Kim W. J., Lee J. Y., Lee S. W., Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury-a systematic review and meta-analysis. Circulation Journal 2012 76 2255 2265
144. Assadi F., Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatric Cardiology 2006 27 2 238 242 2-s2.0-33645120986 10.1007/s00246-005-1132-z
145. Pakfetrat M., Nikoo M. H., Malekmakan L., Tabandeh M., Roozbeh J., Nasab M. H., Ostovan M. A., Salari S., Kafi M., Vaziri N. M., Adl F., Hosseini M., Khajehdehi P., A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial. International Urology and Nephrology 2009 41 3 629 634 2-s2.0-67649989950 10.1007/s11255-008- 9520-y
146. Markota D., Markota I., Starcevic B., Tomic M., Prskalo Z., Brizic I., Prevention of contrast-induced nephropathy with Na/K citrate. European Heart Journal 2013 34 2362 2367
147. Reddan D., Laville M., Garovic V. D., Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? Journal of Nephrology 2009 22 3 333 351 2-s2.0-69449108042
148. Zoungas S., Ninomiya T., Huxley R., Cass A., Jardine M., Gallagher M., Patel A., Vasheghani-Farahani A., Sadigh G., Perkovic V., Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of Internal Medicine 2009 151 9 631 638 2-s2.0-70450220298 10.1059/0003-4819-151-9-200911030-00008
149. Brar S. S., Shen A. Y., Jorgensen M. B., Kotlewski A., Aharonian V. J., Desai N., Ree M., Shah A. I., Burchette R. J., Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. Journal of the American Medical Association 2008 300 9 1038 1046 2-s2.0-50949083026 10.1001/jama.300.9. 1038
150. Brar S. S., Hiremath S., Dangas G., Mehran R., Brar S. K., Leon M. B., Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology 2009 4 10 1584 1592 2-s2.0-73349111614 10.2215/CJN.03120509
151. Shavit L., Korenfeld R., Lifschitz M., Butnaru A., Slotki I., Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. Journal of Interventional Cardiology 2009 22 6 556 563 2-s2.0-71149088484 10.1111/j.1540-8183.2009.00500.x
152. Vasheghani-Farahani A., Sadigh G., Kassaian S. E., Khatami S. M. R., Fotouhi A., Razavi S. A. H., Mansournia M. A., Yamini-Sharif A., Amirzadegan A., Salarifar M., Sadeghian S., Davoodi G., Borumand M. A., Esfehani F. A., Darabian S., Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. American Journal of Kidney Diseases 2009 54 4 610 618 2-s2.0-70349580111 10.1053/j.ajkd.2009.05.016
153. From A. M., Bartholmai B. J., Williams A. W., Cha S. S., Pflueger A., McDonald F. S., Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clinical Journal of the American Society of Nephrology 2008 3 1 10 18 2-s2.0-38749108528 10.2215/CJN.03100707
154. Fliser D., Laville M., Covic A., Fouque D., Vanholder R., Juillard L., van Biesen W., A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury, part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation 2012 27 4263 4272
155. Weisbord S. D., Gallagher M., Kaufman J., Cass A., Parikh C. R., Chertow G. M., Shunk K. A., McCullough P. A., Fine M. J., Mor M. K., Lew R. A., Huang G. D., Conner T. A., Brophy M. T., Lee J., Soliva S., Palevsky P. M., Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clinical Journal of the American Society of Nephrology 2013 8 9 1618 1631
156. Safirstein R., Andrade L., Vieira J. M., Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. The New England Journal of Medicine 2000 343 3 210 212 2-s2.0-0034691667 10.1056/NEJM200007203430311 (Pubitemid 30489222)
157. Lee H. C., Sheu S. H., Liu I. H., Lee C. C., Hsieh C. C., Yen H. W., Lai W. T., Chang J. G., Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. Journal of Nephrology 2012 25 56 62
158. DiMari J., Megyesi J., Udvarhelyi N., Price P., Davis R., Safirstein R., N-acetyl cysteine ameliorates ischemic renal failure. The American Journal of Physiology-Renal Physiology 1997 272 3 F292 F298 2-s2.0-0030764921
159. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. The New England Journal of Medicine 2000 343 3 180 184 2-s2.0-0034691822 10.1056/NEJM200007203430304 (Pubitemid 30489215)
160. Baker C. S. R., Wragg A., Kumar S., de Palma R., Baker L. R. I., Knight C. J., A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. Journal of the American College of Cardiology 2003 41 12 2114 2118 2-s2.0-0038648456 10.1016/S0735-1097(03)00487-X (Pubitemid 36724254)
161. Briguori C., Colombo A., Violante A., Balestrieri P., Manganelli F., Elia P. P., Golia B., Lepore S., Riviezzo G., Scarpato P., Focaccio A., Librera M., Bonizzoni E., Ricciardelli B., Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. European Heart Journal 2004 25 3 206 211 2-s2.0-10744233453 10.1016/j.ehj.2003.11.016 (Pubitemid 38235156)
162. Durham J. D., Caputo C., Dokko J., Zaharakis T., Pahlavan M., Keltz J., Dutka P., Marzo K., Maesaka J. K., Fishbane S., A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney International 2002 62 6 2202 2207 2-s2.0-18744378254 10.1046/j.1523-1755.2002. 00673.x (Pubitemid 35366176)
163. Allaqaband S., Tumuluri R., Malik A. M., Gupta A., Volkert P., Shalev Y., Bajwa T. K., Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheterization and Cardiovascular Interventions 2002 57 3 279 283 2-s2.0-0036843034 10.1002/ccd.10323 (Pubitemid 35266257)
164. Goldenberg I., Shechter M., Matetzky S., Jonas M., Adam M., Pres H., Elian D., Agranat O., Schwammenthal E., Guetta V., Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. European Heart Journal 2004 25 3 212 218 2-s2.0-10744230466 10.1016/j.ehj.2003.11.011 (Pubitemid 38235157)
165. Pannu N., Manns B., Lee H., Tonelli M., Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney International 2004 65 4 1366 1374 2-s2.0-1642545171 10.1111/j.1523-1755.2004.00516.x (Pubitemid 38406975)
166. Coyle L. C., Rodriguez A., Jeschke R. E., Simon-Lee A., Abbott K. C., Taylor A. J., Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. American Heart Journal 2006 151 5 1032.e9 1032.e12 2-s2.0-33646114733 10.1016/j.ahj.2006.02.002
167. Ferrario F., Barone M. T., Landoni G., Genderini A., Heidemperger M., Trezzi M., Piccaluga E., Danna P., Scorza D., Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy-a randomized controlled study. Nephrology Dialysis Transplantation 2009 24 10 3103 3107 2-s2.0-70349482079 10.1093/ndt/gfp306
168. Gurm H. S., Smith D. E., Berwanger O., Share D., Schreiber T., Moscucci M., Nallamothu B. K., Contemporary use and effectiveness of n-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. JACC: Cardiovascular Interventions 2012 5 1 98 104 2-s2.0-84855589639 10.1016/j.jcin.2011.09.019
169. Birck R., Krzossok S., Markowetz F., Schnülle P., van der Woude F. J., Braun C., Acetylcysteine for prevention of contrast nephropathy: meta-analysis. The Lancet 2003 362 9384 598 603 2-s2.0-0042466568 10.1016/S0140-6736(03)14189-X (Pubitemid 37013299)
170. Spargias K., Alexopoulos E., Kyrzopoulos S., Iacovis P., Greenwood D. C., Manginas A., Voudris V., Pavlides G., Buller C. E., Kremastinos D., Cokkinos D. V., Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004 110 18 2837 2842 2-s2.0-8144224968 10.1161/01.CIR.0000146396.19081.73 (Pubitemid 39473606)
171. Alexopoulos E., Spargias K., Kyrzopoulos S., Manginas A., Pavlides G., Voudris V., Lerakis S., McLean D. S., Cokkinos D. V., Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. American Journal of the Medical Sciences 2010 339 1 25 30 2-s2.0-75449083008 10.1097/MAJ.0b013e3181c06e70
172. Boscheri A., Weinbrenner C., Botzek B., Reynen K., Kuhlisch E., Strasser R. H., Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clinical Nephrology 2007 68 5 279 286 2-s2.0-35748975978 (Pubitemid 350047760)
173. Jo S., Koo B., Park J., Kang H., Kim Y., Kim H., Chae I., Choi D., Sohn D., Oh B., Park Y., Choi Y., Kim H., N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study-a prospective randomized controlled trial. American Heart Journal 2009 157 3 576 583 2-s2.0-60949106571 10.1016/j.ahj.2008.11.010
174. Tasanarong A., Vohakiat A., Hutayanon P., Piyayotai D., New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrology Dialysis Transplantation 2013 28 337 344
175. Yang D., Lin S., Yang D., Wei L., Shang W., Effects of short- and long-term hypercholesterolemia on contrast-induced acute kidney injury. American Journal of Nephrology 2012 35 1 80 89 2-s2.0-83755206823 10.1159/000335077
176. Khanal S., Attallah N., Smith D. E., Kline-Rogers E., Share D., O'Donnell M. J., Moscucci M., Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. American Journal of Medicine 2005 118 8 843 849 2-s2.0-23244448755 10.1016/j.amjmed.2005.03.031 (Pubitemid 41097461)
177. Patti G., Nusca A., Chello M., Pasceri V., D'Ambrosio A., Vetrovec G. W., di Sciascio G., Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. The American Journal of Cardiology 2008 101 3 279 285 2-s2.0-38549127836 10.1016/j.amjcard.2007.08.030 (Pubitemid 351162953)
178. Andreucci M., Statins in CIN: a problem at least partly solved? Giornale Italiano di Nefrologia 2013 30 3
179. Han Y., Zhu G., Han L., Hou F., Huang W., Liu H., Gan J., Jiang T., Li X., Wang W., Ding S., Jia S., Shen W., Wang D., Sun L., Qiu J., Wang X., Li Y., Deng J., Li J., Xu K., Xu B., Mehran R., Huo Y., Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology 2013 63 1 62 70
180. Al-Otaibi K. E., Al Elaiwi A. M., Tariq M., Al-Asmari A. K., Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxidative Medicine and Cellular Longevity 2012 2012 8 831748 10.1155/2012/831748
181. Yoshida S., Kamihata H., Nakamura S., Senoo T., Manabe K., Motohiro M., Sugiura T., Iwasaka T., Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. Journal of Cardiology 2009 54 2 192 198 2-s2.0-70349244784 10.1016/j.jjcc.2009.05.006
182. Muñoz M. A., Maxwell P. R., Green K., Hughes D. W., Talbert R. L., Pravastatin versus simvastatin for prevention of contrast-induced nephropathy. Journal of Cardiovascular Pharmacology and Therapeutics 2011 16 3-4 376 379 2-s2.0-80051502308 10.1177/1074248410394362
183. Acikel S., Muderrisoglu H., Yildirir A., Aydinalp A., Sade E., Bayraktar N., Bal U., Ozin B., Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagulation and Fibrinolysis 2010 21 8 750 757 2-s2.0-78349312945 10.1097/MBC.0b013e32834014a4
184. Quintavalle C., Fiore D., de Micco F., Visconti G., Focaccio A., Golia B., Ricciardelli B., Donnarumma E., Bianco A., Zabatta M. A., Troncone G., Colombo A., Briguori C., Condorelli G., Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012 126 3008 3016
185. Leoncini M., Toso A., Maioli M., Tropeano F., Bellandi F., Statin treatment before percutaneous cononary intervention. Journal of Thoracic Disease 2013 5 335 342
186. Zhang B., Li W., Xu Y., High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Canadian Journal of Cardiology 2011 27 6 851 858 2-s2.0-82155185146 10.1016/j.cjca.2011.05.005
187. Patti G., Ricottini E., Nusca A., Colonna G., Pasceri V., D'Ambrosio A., Montinaro A., di Sciascio G., Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. The American Journal of Cardiology 2011 108 1 1 7 2-s2.0-79958816893 10.1016/j.amjcard.2011.03.001
188. Veverka A., Nuzum D. S., Jolly J. L., Nebivolol: a third-generation β -adrenergic blocker. Annals of Pharmacotherapy 2006 40 7-8 1353 1360 2-s2.0-33746990729 10.1345/aph.1G708 (Pubitemid 44204966)
189. Sule S. S., Frishman W., Nebivolol: new therapy update. Cardiology in Review 2006 14 5 259 264 2-s2.0-33748053993 10.1097/01.crd.0000223651.03023.8e (Pubitemid 44298023)
190. Toprak O., Cirit M., Tanrisev M., Yazici C., Canoz O., Sipahioglu M., Uzum A., Ersoy R., Sozmen E. Y., Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrology Dialysis Transplantation 2008 23 3 853 859 2-s2.0-42449136651 10.1093/ndt/gfm691 (Pubitemid 351767560)
191. Avci E., Yeşil M., Bayata S., Postaci N., Arikan E., Cirit M., The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyoloji Dergisi 2011 11 7 613 617 2-s2.0-80054694709 10.5152/akd.2011.164
192. Günebakmaz Ö., Kaya M. G., Koc F., Akpek M., Kasapkara A., Inanc M. T., Yarlioglues M., Calapkorur B., Karadag Z., Oguzhan A., Does nebivolol prevent contrast-induced nephropathy in humans? Clinical Cardiology 2012 35 4 250 254 2-s2.0-84859775816 10.1002/clc.21013
193. Kodama A., Watanabe H., Tanaka R., Tanaka H., Chuang V. T., Miyamoto Y., Wu Q., Endo M., Hamasaki K., Ishima Y., Fukagawa M., Otagiri M., Maruyama T., A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. Kidney International 2013 83 446 454
194. Machado R. A., Constantino Lde S., Tomasi C. D., Rojas H. A., Vuolo F. S., Vitto M. F., Cesconetto P. A., de Souza C. T., Ritter C., Dal-Pizzol F., Sodium butyrate decreases the activation of NF-kappaB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrology Dialysis Transplantation 2012 27 3136 3140
195. Ribichini F., Gambaro A., Pighi M., Pesarini G., Ferraro P. M., Zuppi C., Baroni S., Penitente R., Ferrero V., Vassanelli C., Effects of prednisone on biomarkers of tubular damage induced by radiocontrast in interventional cardiology. Journal of Nephrology 2013 26 586 593
196. Kumar S., Allen D. A., Kieswich J. E., Patel N. S. A., Harwood S., Mazzon E., Cuzzocrea S., Raftery M. J., Thiemermann C., Yaqoob M. M., Dexamethasone ameliorates renal ischemia-reperfusion injury. Journal of the American Society of Nephrology 2009 20 11 2412 2425 2-s2.0-72049093258 10.1681/ASN.2008080868
197. Rudnick M. R., Goldfarb S., Wexler L., Ludbrook P. A., Murphy M. J., Halpern E. F., Hill J. A., Winniford M., Cohen M. B., VanFossen D. B., Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney International 1995 47 1 254 261 2-s2.0-0028936849
198. Romano G., Briguori C., Quintavalle C., Zanca C., Rivera N. V., Colombo A., Condorelli G., Contrast agents and renal cell apoptosis. European Heart Journal 2008 29 20 2569 2576 2-s2.0-54149089710 10.1093/eurheartj/ehn197
199. From A. M., Al Badarin F. J., McDonald F. S., Bartholmai B. J., Cha S. S., Rihal C. S., Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy meta-analysis of randomized, controlled trials. Circulation: Cardiovascular Interventions 2010 3 4 351 358 2-s2.0-78650092846 10.1161/CIRCINTERVENTIONS.109.917070
200. Biondi-Zoccai G., Lotrionte M., Thomsen H. S., Romagnoli E., D'Ascenzo F., Giordano A., Frati G., Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis. International Journal of Cardiology 2014 172 2 375 380
201. Keaney J. J., Hannon C. M., Murray P. T., Contrast-induced acute kidney injury: how much contrast is safe? Nephrology Dialysis Transplantation 2013 28 1376 1383
202. Cigarroa R. G., Lange R. A., Williams R. H., Hillis L. D., Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. American Journal of Medicine 1989 86 6 I 649 652 2-s2.0-0024392252 (Pubitemid 19149343)
203. Laskey W. K., Jenkins C., Selzer F., Marroquin O. C., Wilensky R. L., Glaser R., Cohen H. A., Holmes D. R. Jr., Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. Journal of the American College of Cardiology 2007 50 7 584 590 2-s2.0-34547606301 10.1016/j.jacc.2007. 03.058 (Pubitemid 47199002)
204. Mager A., Vaknin Assa H., Lev E. I., Bental T., Assali A., Kornowski R., The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Catheterization and Cardiovascular Interventions 2011 78 2 198 201 2-s2.0-79960734214 10.1002/ccd.22828
205. Gurm H. S., Dixon S. R., Smith D. E., Share D., Lalonde T., Greenbaum A., Moscucci M., Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology 2011 58 9 907 914 2-s2.0-84860390259 10.1016/j.jacc.2011.05.023
206. Weinstein J.-M., Heyman S., Brezis M., Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992 62 4 413 415 2-s2.0-0026476667
207. Weisberg L. S., Kurnik P. B., Kurnik B. R. C., Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney International 1994 45 1 259 265 2-s2.0-0028032093 (Pubitemid 24046017)
208. Majumdar S. R., Kjellstrand C. M., Tymchak W. J., Hervas-Malo M., Taylor D. A., Teo K. K., Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. American Journal of Kidney Diseases 2009 54 4 602 609 2-s2.0-70349243208 10.1053/j.ajkd.2009.03.024
209. Kurnik B. R. C., Allgren R. L., Center F. C., Solomon R. J., Bates E. R., Weisberg L. S., Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. American Journal of Kidney Diseases 1998 31 4 674 680 2-s2.0-0031897391 (Pubitemid 28158009)
210. 2+exchange inhibitor, KB-R7943, attenuates contrast-induced acute kidney injury. Journal of Nephrology 2013 26 877 885
211. Neumayer H.-H., Junge W., Kufner A., Wenning A., Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrology Dialysis Transplantation 1989 4 12 1030 1036 2-s2.0-0024938617 (Pubitemid 20135461)
212. Russo D., Testa A., della Volpe L., Sansone G., Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990 55 3 254 257 2-s2.0-0025290157 (Pubitemid 20209507)
213. Khoury Z., Schlicht J. R., Como J., Karschner J. K., Shapiro A. P., Mook W. J., Weber R. J., The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995 15 1 I 59 65 2-s2.0-0028890871
214. Spangberg-Viklund B., Berglund J., Nikonoff T., Nyberg P., Skau T., Larsson R., Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scandinavian Journal of Urology and Nephrology 1996 30 1 63 68 2-s2.0-0030010137
215. Erley C. M., Duda S. H., Schlepckow S., Koehler J., Huppert P. E., Strohmaier W. L., Bohle A., Risler T., Osswald H., Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney International 1994 45 5 1425 1431 2-s2.0-0028197346 (Pubitemid 24135030)
216. Katholi R. E., Taylor G. J., McCann W. P., Woods W. T. Jr., Womack K. A., McCoy C. D., Katholi C. R., Moses H. W., Mishkel G. J., Lucore C. L., Holloway R. M., Miller B. D., Woodruff R. C., Dove J. T., Mikell F. L., Schneider J. A., Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995 195 1 17 22 2-s2.0-0028938497
217. Erley C. M., Duda S. H., Rehfuss D., Scholtes B., Bock J., Müller C., Osswald H., Risler T., Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrology Dialysis Transplantation 1999 14 5 1146 1149 2-s2.0-0032922515 10.1093/ndt/14.5.1146 (Pubitemid 29209299)
218. Huber W., Ilgmann K., Page M., Hennig M., Schweigart U., Jeschke B., Lutilsky L., Weiss W., Salmhofer H., Classen M., Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002 223 3 772 779 2-s2.0-0036107523 (Pubitemid 34547597)
219. Kapoor A., Kumar S., Gulati S., Gambhir S., Sethi R. S., Sinha N., The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrology Dialysis Transplantation 2002 17 11 1936 1941 2-s2.0-0036843103 (Pubitemid 35277091)
220. Abizaid A. S., Clark C. E., Mintz G. S., Dosa S., Popma J. J., Pichard A. D., Satler L. F., Harvey M., Kent K. M., Leon M. B., Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. The American Journal of Cardiology 1999 83 2 260 263, A265 2-s2.0-0033556380 10.1016/S0002-9149(98) 00833-9 (Pubitemid 29047309)
221. Shammas N. W., Kapalis M. J., Harris M., McKinney D., Coyne E. P., Aminophylline does not protect against Radiocontrast Nephropathy in patients undergoing percutaneous angiographic procedures. Journal of Invasive Cardiology 2001 13 11 738 740 2-s2.0-0035511838 (Pubitemid 33759909)
222. Hans S. S., Hans B. A., Dhillon R., Dmuchowski C., Glover J., Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. American Surgeon 1998 64 5 432 436 2-s2.0-0031979049 (Pubitemid 28208787)
223. Chamsuddin A. A., Kowalik K. J., Bjarnason H., Dietz C. A., Rosenberg M. S., Gomes M. D., McDermott C. M., Hunter D. W., Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. American Journal of Roentgenology 2002 179 3 591 596 2-s2.0-0036720583 (Pubitemid 34919564)
224. Kini A. S., Mitre C. A., Kamran M., Suleman J., Kim M., Duffy M. E., Marmur J. D., Sharma S. K., Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. The American Journal of Cardiology 2002 89 8 999 1002 2-s2.0-0037090381 10.1016/S0002-9149(02)02259-2 (Pubitemid 34310307)
225. Stone G. W., McCullough P. A., Tumlin J. A., Lepor N. E., Madyoon H., Murray P., Wang A., Alan Chu A., Schaer G. L., Stevens M., Wilensky R. L., O'Neill W. W., Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. Journal of the American Medical Association 2003 290 17 2284 2291 2-s2.0-0242493661 10.1001/jama.290.17.2284 (Pubitemid 37430561)
226. Wang A., Holcslaw T., Bashore T. M., Freed M. I., Miller D., Rudnick M. R., Szerlip H., Thames M. D., Davidson C. J., Shusterman N., Schwab S. J., Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney International 2000 57 4 1675 1680 2-s2.0-0034115616 10.1046/j.1523-1755. 2000.00012.x (Pubitemid 30207926)
227. Koch J., Plum J., Grabensee B., Mödder U., Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrology Dialysis Transplantation 2000 15 1 43 49 2-s2.0-0033631889 (Pubitemid 30037929)
228. Lehnert T., Keller E., Gondolf K., Schäffner T., Pavenstädt H., Schollmeyer P., Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrology Dialysis Transplantation 1998 13 2 358 362 2-s2.0-0031976079 (Pubitemid 28062196)
229. Schindler R., Stahl C., Venz S., Ludat K., Krause W., Frei U., Removal of contrast media by different extracorporeal treatments. Nephrology Dialysis Transplantation 2001 16 7 1471 1474 2-s2.0-0034934210 (Pubitemid 32640606)
230. Vogt B., Ferrari P., Schönholzer C., Marti H., Mohaupt M., Wiederkehr M., Cereghetti C., Serra A., Huynh-Do U., Uehlinger D., Frey F. J., Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. American Journal of Medicine 2001 111 9 692 698 2-s2.0-0035893636 10.1016/S0002-9343(01)00983-4 (Pubitemid 34017520)
231. Esnault V. L. M., Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. Nephrology Dialysis Transplantation 2002 17 8 1362 1364 2-s2.0-0035993265
232. Wood S. P., Contrast-induced nephropathy in critical care. Critical Care Nurse 2012 32 15 23
233. Kallen A. J., Jhung M. A., Cheng S., Hess T., Turabelidze G., Abramova L., Arduino M., Guarner J., Pollack B., Saab G., Patel P. R., Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. American Journal of Kidney Diseases 2008 51 6 966 975 2-s2.0-44049099289 10.1053/j.ajkd.2007.12.036 (Pubitemid 351711602)
234. Bahrami S., Raman S. S., Sauk S., Salehmoghaddam S., Villablanca J. P., Finn J. P., Lu D. S. K., Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. Journal of Computer Assisted Tomography 2009 33 6 819 823 2-s2.0-73949113452 10.1097/RCT.0b013e31819d68ed
235. Andreucci M., Contrast media and nephrotoxicity: a molecular conundrum. Giornale Italiano di Nefrologia 2011 28 4, article 355